Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTG-321 for knee osteoarthritis pain
2026-525966-22-00Phase 2Authorised
- Sponsor
- Latigo Biotherapeutics
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LTG-321 in knee osteoarthritis (OA) (2 arms), sponsored by Latigo Biotherapeutics. Primary endpoint: Change in WOMAC pain subscale score. Planned start Jun 2026; status: authorised.
02
Drugs
LTG-321
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2026-525966-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525966-22-00.